100%.
Not most. Not a strong majority. Every single oncologist surveyed.
In a study out of Johns Hopkins, researchers asked oncology professionals about the impact of prior authorization on their patients. The result should be a turning point for anyone still defending the current system: 100% of them reported patient harm.
The numbers behind the headline
The Johns Hopkins study didn’t stop at the top-line finding. The details are worse:
- 80% of oncologists witnessed their patients’ cancer progress while waiting for prior authorization
- 36% watched a patient die during the authorization process
- 100% reported some form of measurable patient harm
Let that sink in. More than a third of oncologists surveyed have had a patient die while they waited for an insurance company to decide whether they were allowed to treat cancer.
These are not marginal cases
These aren’t doctors who don’t know what they’re doing. These are oncologists — physicians who have spent 13+ years in training. They’ve completed medical school, residency, and fellowship. They’ve passed board certification. They know what their patients need.
And they’re being told to wait by a system whose economic incentive is to say no, or at least to say “not yet.”
The language tells the story
Consider the word “authorization.” We speak as if the physician is requesting permission to do their job. As if a board-certified oncologist needs approval from an insurance company employee to treat cancer.
What prior authorization actually authorizes, in too many cases, is delay. It authorizes suffering. And in 36% of these cases, it authorized death.
Why oncology is the canary in the coal mine
Oncology makes the stakes of prior authorization impossible to ignore because cancer doesn’t wait. A tumor doesn’t pause its growth while paperwork moves through a queue. A window for early intervention doesn’t reopen because an appeal was eventually approved.
But oncology isn’t unique. The same dynamic plays out across cardiology, neurology, rheumatology, and every other specialty where timely treatment matters — which is to say, all of them. The difference is that in oncology, the consequences are immediate and measurable.
What needs to change
The prior authorization process was designed as a cost-control mechanism. Whatever its original intent, the data is now clear: it is causing measurable, documented patient harm at a scale that should be unacceptable to every stakeholder in healthcare.
The solutions exist. Electronic prior authorization, AI-powered clinical documentation, and payer intelligence systems can reduce authorization turnaround from days to hours. The technology is here. The question is whether the industry will adopt it before more patients pay the price for administrative friction.
At Artificer Health, we’re building exactly this — a platform that makes prior authorizations painless, because the current system is anything but. We’re recruiting pilot partners who are ready to stop losing patients to paperwork.
Source: Johns Hopkins Medicine — Researchers Find Measurable Patient Harm Linked to Prior Authorization